Citigroup’s PhenomeX Inc. Common Stock CELL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,963
Closed -$2.28K 5814
2023
Q1
$2.28K Sell
1,963
-433
-18% -$792 ﹤0.01% 5081
2022
Q4
$6.42K Buy
2,396
+1,504
+169% +$3.96K ﹤0.01% 4979
2022
Q3
$3K Sell
892
-3,338
-79% -$14.2K ﹤0.01% 5442
2022
Q2
$21K Sell
4,230
-1,243
-23% -$6.51K ﹤0.01% 4990
2022
Q1
$39K Sell
5,473
-86,154
-94% -$713K ﹤0.01% 4845
2021
Q4
$1.67M Buy
91,627
+1,747
+2% +$37.7K ﹤0.01% 2770
2021
Q3
$1.76M Sell
89,880
-2,417
-3% -$91.9K ﹤0.01% 2638
2021
Q2
$4.14M Buy
92,297
+1,528
+2% +$70.8K ﹤0.01% 2062
2021
Q1
$4.56M Buy
90,769
+53,348
+143% +$3.64M ﹤0.01% 1849
2020
Q4
$3.35M Buy
37,421
+34,974
+1,429% +$2.94M ﹤0.01% 2383
2020
Q3
$186K Buy
+2,447
New +$155K ﹤0.01% 4664

Other funds holding CELL

Citigroup's CELL Position: Q2 2023 in Review

Citigroup sold out of PhenomeX Inc. Common Stock (CELL) in Q2 2023, closing a stake of 1,963 shares — an estimated $2.28K sold.

Citigroup first reported a position in CELL in Q3 2020 and held it in 11 quarters. The position peaked at $4.56M in Q1 2021. 84 funds tracked by Wall St. Rank hold CELL as of Q2 2023.

  • Citigroup reported no remaining PhenomeX Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Citigroup sold 1,963 PhenomeX Inc. Common Stock shares in Q2 2023, an estimated $2.28K.
  • Citigroup first reported a position in PhenomeX Inc. Common Stock in Q3 2020 and held it in 11 quarters.
  • Citigroup's PhenomeX Inc. Common Stock position peaked at $4.56M in Q1 2021.
  • 84 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q2 2023.

Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.